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Abstract
Background: Iron is a vital nutrient for all cells, and malignant cells have a higher requirement for the metal due to
their rapid multiplication. Bacterial siderophores can be used to reduce free ferric ion concentration from the
cellular environment.
Methods: In the present study, we have evaluated effect of three siderophores – exochelin-MS, mycobactin S and
deferoxamine B on the proliferation of mammalian cell lines using MTT assay.
Results: These siderophores caused a significant decrease in the viability of malignant cells, without significantly
affecting non-malignant cells.
Conclusions: Based on these results, we suggest that iron-chelation therapy could be explored as an adjunctive
therapeutic option against cancer along with other therapies.
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Background
Iron is a vital nutrient for all cells. In eukaryotes,
the highly iron-dependent activity of ribonucleotide
reductase is essential for cell division [1]. Under
iron-deficient conditions, cells cannot transit from
G1-phase to S-phase in the cell cycle. Neoplastic
cells have a higher requirement for iron than nor-
mal cells as they proliferate at a faster rate. There-
fore, iron depletion by iron-chelating agents may
deprive the rapidly dividing malignant cells of the
DNA precursors required for replication, resulting
in the inhibition of their proliferation [2, 3].
Bacterial iron chelators termed siderophores can
be used for reducing free iron concentration in the
cellular environment. Growing microbial cells in
iron-deficient laboratory growth media allows isola-
tion and characterization of the siderophores.
Exochelin-MS (Exo-MS) is a water-soluble siderophore
and mycobactin S (MBS) is a lipid-soluble siderophore
produced by Mycobacterium smegmatis. Water-soluble
deferoxamine mesylate B (DFO-B), originally from Strep-
tomyces pilosus, is now commercially available.
Effect of Exo-MS, MBS and DFO-B were evaluated
individually on malignant and non-malignant cell lines
of murine and human origin. The concept tested here
was whether iron deprivation by microbial sidero-
phores affects multiplication of mammalian cells. This
was assessed in vitro by MTT assay.
Methods
For the production of siderophores from M. smegma-
tis mc2155, iron-deficient minimal medium was used
[4, 5]. The culture of M. smegmatis mc2155 was inoc-
ulated and incubated at 37 °C for 10 days on the
shaker at 200 rpm for Exo-MS production; whereas,
for the production of MBS, the culture flasks were in-
cubated at 37 °C for 10 days under static conditions.
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Extraction, detection and purification of Exo-MS
(a)Extraction of Exo-MS:
The10-day old culture broth of M. smegmatis was cen-
trifuged at 10,000 rpm for 10 min to pellet the cells. The
supernatant, in batches of 100 mL was freeze-dried, sub-
sequently redissolved in 10 mL of distilled water and the
pH was adjusted to 3.5. Then, it was saturated with am-
monium sulfate (76 g/100 mL), and kept at 4 °C over-
night. Next day, the solution was centrifuged and the
supernatant was transferred to a 50 mL tube and treated
with 2.0 mL of benzyl alcohol. The aqueous and the
solvent phases were mixed vigorously, centrifuged and
the upper phase of benzyl alcohol fraction was collected
in a clean test tube. This extraction step was repeated
three times and all the benzyl alcohol fractions were
pooled [6]. The pooled extract was mixed with 8.0 mL
of diethyl ether for partitioning the water soluble Exo-
MS. Exo-MS was extracted with 1.0 mL of distilled
water. The solvent-water mixture was centrifuged, and
the lower aqueous phase was transferred to a clean tube.
This step too was repeated thrice with 1.0 mL distilled
water each time. All the aqueous fractions were pooled
and washed with diethylether to remove traces of benzyl
alcohol. This aqueous Exo-MS preparation was concen-
trated by freeze-drying which also removed any residual
diethyl ether.
(b)Purification and Detection of Exo-MS:
The Exo-MS extract was purified on a column of neu-
tral grade alumina. When the column was eluted with
petroleum spirit (bp = 60 to 80 °C), the Exo-MS was
firmly bound to the alumina, whereas the faster-
migrating compounds were washed away with no retard-
ation. Hydrophobic impurities were removed from the
alumina-bound Exo-MS by sequential washes with
cyclohexane, toluene, diethyl ether, ethyl acetate, and
chloroform; all the washes were discarded. The adsorbed
Exo-MS was then eluted from the column with the
methanol-formic acid (4:1, v/v) mixture [7]. The eluate
was concentrated by freeze-drying and neutralized to
pH 6.5. The concentration of this Exo-MS preparation
was determined by UV spectrophotometer.
The Exo-MS preparation was also subjected to high-
resolution liquid chromatography/mass spectrometry
(HR-LC/MS) using Agilent Technologies Q-TOF Mass
Spectrometer system at Sophisticated Analytical Instru-
ment Facility, Indian Institute of Technology Bombay,
India. The solvent system was 95 mL of 0.1% of Trifluor-
oacetic acid (TFA) in water with 5 mL of 0.1% TFA in
90% Acetonitrile (ACN) for 22 min. Then, 5 mL of 0.1%
of Trifluoroacetic acid (TFA) in water with 95 mL of
0.1% TFA in 90% Acetonitrile (ACN) for 9 min. This
was followed by the first solvent mixture for 5 min. The
flow-rate was 0.4 mL/min for 35 min with maximum
pressure of 1200 bar.
Two dimensional nuclear magnetic resonance - total
correlation spectroscopy (2D-NMR-TOCSY) was carried
out at National Facility for High-Field NMR, Tata Insti-
tute of Fundamental Research, Mumbai, India. The solv-
ent system was 10% D2O and 90% water, which was run
for 2 h on 500 MHz instrument.
Extraction, detection and purification of MBS
(a)Extraction of MBS:
The 10-day old culture broth of M. smegmatis mc2155
was centrifuged and the cell pellet was transferred to a
flask containing 100 mL of ethanol and kept overnight
in the refrigerator. Next day, this extract was mixed with
equal volume of chloroform. Sufficient water was added
to this mixture to form two layers. The upper aqueous
layer was discarded, and the lower chloroform layer con-
taining MBS was washed with water, dehydrated over
anhydrous Na2SO4 and evaporated to dryness. The dried
residue was extracted with methanol at room
temperature. The methanol-soluble MBS was thus sepa-
rated from the other insoluble impurities [8].
(b)Purification and Detection of MBS:
Methanol-soluble MBS was evaporated to dryness and
then dissolved in a minimum amount of tertiary butanol
: cyclohexane (1:1, v/v) ratio. After dissolving the resi-
due, cyclohexane was added further to make up the vol-
ume to 100 mL. This solution was then adsorbed onto
neutral grade alumina in a beaker and washed with
50 mL of cyclohexane. The wash was discarded. The
adsorbed material was then sequentially washed with
50 mL each of petroleum ether, toluene and diethyl
ether, which were also discarded. Finally, MBS was
eluted using chloroform: acetone mixture (1:1, v/v) [9].
This eluate was evaporated to dryness again, dissolved in
absolute ethanol and subjected to Sephadex LH 20 col-
umn chromatography. MBS was eluted using absolute
ethanol. UV spectrophotometer was used to determine
the concentration of this MBS preparation.
Reverse-phase HPLC was used to confirm the purity
of MBS after adding 10 μL of 10% ethanolic ferric chlor-
ide to 100 μL of the MBS preparation to get ferri-MBS,
which was carried out on Waters Xterra MS MS system
at Bombay College of Pharmacy, Mumbai, India. The
gradient solvent system used for HPLC was methanol:
water (80:20, v/v) which was passed through a C18 col-
umn for 30 min and then with 100% methanol for the
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next 15 min. The column used was, C18, 5 μm, 4.6 ×
100 mm at the flow-rate of 1.5 mL per min. The eluted
peaks were determined by monitoring the absorbance of
the sample at A220nm and A450nm.
Purity analysis of DFO-B
DFO-B manufactured by Novartis, Switzerland, and ob-
tained as 500 mg dry powder was dissolved in 2 mL ster-
ile water at a concentration of 250 mg /mL. For HPLC,
ferrioxamine-B was prepared by mixing 10 μL of 10%
aqueous ferric chloride to 100 μL of 1.0 mg/mL DFO-B.
Gradient solvent system used was 0.1% Trifluoroacetic
acid (TFA) in water for 10 min, then equal volumes of
0.1% aqueous TFA and acetonitrile (ACN) (1:1, v/v) for
30 min and 0.1% TFA in water for 10 min. The column
used was C18, 5 μm, 4.6 × 100 mm, at a flow-rate of
1.5 mL per min. The peaks were monitored by measur-
ing the absorbance at 420 nm. This analysis was carried
out on Waters Xterra MS MS system at Bombay College
of Pharmacy, Mumbai, India.
Determination of the effect of Exo-MS, DFO-B, and MBS
on mammalian cell lines
The effect of Exo-MS, DFO-B, and MBS was evaluated
using malignant and non-malignant mammalian cell
lines. A working stock solution of DFO-B at 100 mg/mL
was prepared from 250 mg/mL stock solution before
use. Exo-MS was dissolved in water and MBS in metha-
nol for use.
Cell Lines: The cell lines used were as follows:
 Adherent malignant cell lines - RAW 264.7 (murine
macrophage), MCF-7 (human breast), HEPG2 (hu-
man liver);
 Non-adherent malignant cell line – K 562 (human
leukemia);
 Adherent non-malignant cell lines - NIH/3 T3
(mouse embryonic fibroblast) and HEK 293 (human
embryonic kidney).
The cell lines were procured from NCCS, Pune, India.
They were maintained in T-25 flasks in Dulbecco’s
Modified Eagle’s Medium (DMEM) with 10% Fetal Bo-
vine serum (FBS) at 37 °C in a CO2 incubator with 5%
CO2 in humidified air.
Cell culture growth medium: DMEM, FBS and
Trypsin-EDTA were obtained from Cell Clone (Genetix
Biotech Asia, India).
Cell viability assay using MTT reagent: MTT {3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide}
assay was used to determine the viability of cells. This
assay is a useful quantification method which measures
metabolic activity of cells [10, 11]. Metabolically active
cells reduce yellow-colored tetrazolium and form purple
crystals of formazan. These crystals upon solubilization
with DMSO (dimethyl sulfoxide) were quantified by
measuring the absorbance at 570 nm and 655 nm using
a microplate reader.
All the cells used in the study were seeded in tripli-
cates at a concentration of 6 × 104 cells/mL of complete
DMEM in 12-well plates (total volume was 1.0 mL) and
incubated for 24 h. Next day, different concentrations of
each of the siderophores – Exo-MS, DFO-B, and MBS
were added and incubated for another 24 h. Since MBS
was prepared in methanol, methanol control was also
maintained, where the cells were incubated with only
methanol. The assay contained:
 Blank wells with only medium;
 Control wells with untreated cells;
 Control wells with cells treated with sodium azide;
 Test wells with cells treated with the siderophores.
Next day, from adherent cells, spent medium was dis-
carded, and 1.0 mL of MTT reagent in DMEM was
added to the wells and incubated at 37 °C for 4 h. For
the non-adherent cell line, the entire suspension was
centrifuged in a 1.5 mL microfuge tube to pellet the
cells. The supernatant was carefully poured out, and the
cell pellet was then resuspended in 1.0 mL of MTT re-
agent, reloaded in the same wells and incubated for 4 h
at 37 °C. At the end of the incubation period, 1.0 mL of
100% DMSO was added to solubilize the visible forma-
zan crystals. The plates were placed on a rocker for
20 min, and the absorbance of each well was measured
at 570 nm and 655 nm using Epoch 2 (Biotek Instru-
ments, USA) instrument.
MTT assays for every cell line were performed as three
independent experiments, each in triplicate. Statistical
analytical software - GraphPad Prism 7.01 and SigmaStat
4.0 – were used to compare the effect of Exo-MS, DFO-
B and MBS on each cell line. The readings of control
wells containing untreated cells were considered as
100% survival. The readings of control wells containing
cells treated with 0.1% sodium azide were considered as
no survival.
Results
Purity analysis of siderophores
i) The HR-LC/MS of ferri-Exo-MS showed many
peaks at 420 nm from 0 to 30 min (Fig. 1a and
Table 1). The major peak was between 24 and
25 min. The area under this curve was considered to
be 100% and the relative concentrations of the other
peaks were measured.
The MS-MS results showed a significant peak corre-
sponding to a molecular weight of 663 indicating
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presence of Exo-MS (Fig. 1b). The second major
peak had a molecular weight of 326 indicating the
presence of doubly charged Exo-MS.
For 2D NMR-TOCSY of Exo-MS, the concentration
used was 800 μg/mL. The analysis was done on a
500 MHz instrument with 10% D2O in water for 2
h. The chromatogram obtained showed the spin sys-
tems of threonine, β-alanine and γ1 β-ornithine
(Fig. 2).
ii) HPLC of ferri-MBS: HPLC analysis of ferri-MBS
showed peaks in order of increasing acyl-chain
length, which were visualized as seven peaks at
450 nm (Fig. 3a), when 10 μL of 4 mg/mL concen-
tration of MBS was used. Three peaks were seen be-
tween 5 and 10 min, one major peak between 10
and 15 min along with a minor peak. The sixth and
seventh peaks were seen between 20 and 25 min and
between 35 and 40 min, respectively. The absorb-
ance of ferri-MBS at 220 nm (Fig. 3b) was measured
to know the extent of purity of the MBS preparation.
The peaks at 220 nm were at the same positions as
that seen at 450 nm.
Fig. 1 HR-LC/MS of ferri-exochelin-MS: Exo-MS preparation was analyzed by injecting 5 μL volume in the column. Agilent system Q-TOF Mass
Spectrometer was used. The solvent system was 95 mL of 0.1% of Trifluoroacetic acid (TFA) in water with 5 mL of 0.1% TFA in 90% Acetonitrile
(ACN) for 22 min. Then, 5 mL of 0.1% of Trifluoroacetic acid (TFA) in water with 95 mL of 0.1% TFA in 90% Acetonitrile (ACN) for 9 min. This was
followed by the first solvent mixture for 5 min. The flow-rate was 0.4 mL/min for 35 min with maximum pressure of 1200 bar. a High-resolution
liquid chromatogram: The peak seen between 24.036 and 25.271 showed the maximum area which was used for further resolution and detection
by MS. b Mass spectrometry of the peak at 24 min from (a). Peaks at 663.45 and 326.37 are due to MH+ and MH22+, respectively
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iii)The HPLC chromatogram of ferrioxamine B showed
a single sharp peak between 15 and 20 min (Fig. 4).
Gradient Trifluoroacetic acid-Acetonitrile (TFA-
ACN) solvent system was used for analysis of 10 μL
of 1.0 μg/mL concentration of ferrioxamine B.
To determine the concentration of purified sidero-
phores, A420nm of Exo-MS and A450nm of MBS were
measured using UV-VIS spectrophotometer. As per
Ratledge and Ewing [12], the extinction coefficients are:
Exo-MS: E1cm
1% = 15.8 in water;
MBS: E1cm
1% = 43 in water;
Using the above correlations, the concentrations of
siderophores purified for use in these assays were Exo-
MS = 19 mg/mL and MBS = 4 mg/mL.
Effect of Exo-MS, MBS, and DFO-B on mammalian cell
lines
The MTT reagent exhibited negligible background ab-
sorbance values in blank wells without the cells. The ab-
sorbance values of untreated cells were considered as
100%. The absorbance reading from each well, (A570nm -
Table 1 HR-LC/MS integration peak list of Exo-MS
Peak Start RT End Height Area Area % AreaSumPercent BasePeakMz
1 0.423 0.474 0.574 1605457 7925924 20.49 5.51 150.1117
2 0.641 0.691 0.741 1260173 3247945 8.4 2.26 139.0495
3 5.433 5.517 5.617 929895 3587468 9.27 2.5 453.3415
4 9.274 9.357 9.441 2115277 5968077 15.43 4.15 568.2943
5 9.508 9.574 9.675 1806352 5584557 14.44 3.89 383.1507
6 15.853 16.054 16.438 2043093 25462871 65.83 17.72 326.377
7 18.024 18.108 18.225 3059381 14141487 36.56 9.84 311.1631
8 19.56 19.711 19.945 1145362 9522103 24.62 6.63 338.34
9 21.397 21.497 21.614 2927045 14662592 37.91 10.2 413.2648
10 24.036 24.654 25.271 1030920 38679784 100 26.91 663.451
Fig. 2 The two-dimensional nuclear magnetic resonance spectroscopy 2D NMR-TOCSY of ferri-Exo-MS. Exo-MS at a concentration of 800 μg/mL
was analyzed on a 500 MHz instrument with 10% D2O in water for 2 h. The spin systems of threonine, β-alanine and γ1 β-ornithine are seen
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A655nm) was calculated, and then the following formula
was used to determine the percent survival;




The intensity of purplish pink colour produced is dir-
ectly proportional to the number of viable cells. The
readings of control wells containing untreated cells
which were considered as 100% survival showed a dark
purple colour. The readings of control wells containing
cells treated with 0.1% sodium azide showed either very
pale purple colour or were colourless (data not shown).
Murine cell lines - RAW 264.7 and NIH/3 T3: A
statistically significant decrease in the percent sur-
vival of RAW 264.7 was seen at Exo-MS concentra-
tions of 0.2 mg/mL, where percentage of viable cells
was 34% (Fig. 5a). No significant effect was seen on
normal mouse fibroblast cell line NIH/3 T3 at Exo-
MS concentrations up to 0.5 mg/mL. Percent cell
survival was 100, 83 and 67% at 0.1 mg/mL, 0.2 mg/
mL and 0.5 mg/mL, respectively (Fig. 5b). Figure 5c
shows the IC50 of Exo-MS for RAW 264.7 which
was 0.128 mg/mL.
A statistically significant decrease in the percent
survival of RAW 264.7 was seen at DFO-B at
Fig. 3 HPLC of pure ferri-mycobactin S. MBS at 4 mg/mL concentration was analyzed by injecting 10 μL volume in Waters Xterra MS MS HPLC
system. The column used was C18, 5 μm, 4.6 × 100 mm at the flow-rate of 1.5 mL per min. Solvent system was methanol: water (80:20, v/v) for
30 min followed by 100% methanol for 15 min. (a) at 450 nm; (b) 220 nm. Seven peaks of different intensities were observed depending upon
the acyl chain length that varies from 9 to 19 carbons; the shortest chain being eluted out first and the longest last
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concentrations up to 1.0 mg /mL, where percent cell
survival was 38, 30 and 11% at 0.1 mg/mL, 0.2 mg/
mL and 1 mg/mL, respectively (Fig. 6a). No signifi-
cant effect was seen on normal mouse fibroblast cell
line NIH/3 T3 at DFO-B concentrations up to
1.0 mg/mL. Percent cell survival was 100, 94 and 87%
at 0.1 mg/mL, 0.2 mg/mL and 1 mg/mL, respectively
(Fig. 6b). Figure 6c shows that the IC50 of DFO-B for
RAW 264.7 which was 0.366 mg/mL.
Human Cell Lines – K 562, MCF-7, HEK 293
No statistically significant decrease in the percent sur-
vival of K 562 and MCF-7 at Exo-MS concentrations at
0.5 mg/mL and 1.0 mg/mL, respectively, was observed.
For K 562, percent survival was 94 and 82%, respectively
(Fig. 7a) and for MCF-7, it was 100 and 88.5%, respect-
ively (Fig. 7b). Similarly, no significant decrease in the
percent survival of HEK 293 at Exo-MS concentrations
up to 1.0 mg/mL was observed. Percent cell survival at
Exo-MS concentrations 0.2 mg/mL and 0.5 mg/mL for
HEK 293 was 92 and 90%, respectively (Fig. 7c).
The percent viability of K 562, MCF-7, HEK 293 in
the presence of DFO-B. For K 562, a statistically signifi-
cant reduction in cell survival at DFO-B concentration
of 0.5 mg/mL was observed, (P <0.01). Percent cell sur-
vival at DFO-B concentrations – 0.5 mg/mL and 1 mg/
mL for K 562 was 55 and 54%, respectively (Fig. 8a).
There was a statistically significant reduction in the
percent cell survival of breast cancer cell line MCF-7 at
DFO-B concentration of 1.0 mg/mL, (P <0.01). Percent
cell survival at DFO-B concentration of 1 mg/mL for
MCF-7 was 62% (Fig. 8b).
There was no statistically significant decrease in the
percent survival of HEK 293. Percent cell survival at
DFO-B concentrations – 0.5 mg/mL and 1 mg/mL for
HEK 293 was 92 and 88%, respectively (Fig. 8c).
There was a statistically significant decrease in via-
bility of HEPG2 cells at MBS concentrations from
10 μg/mL onwards (P <0.001). Percent cell survival at
MBS concentrations of 5 μg/mL, 10 μg/mL and
20 μg/mL were 92.4, 48 and 23%, respectively (Fig. 9a).
Methanol did not have any statistically significant ef-
fect on the cells since 95% survival of cells was ob-
served (data not shown). Figure 9b and c show that
there was no statistically significant decrease in per-
cent survival of HEPG2 at the Exo-MS and DFO-B
concentrations as high as 1 mg/mL and 10 mg/mL,
respectively.
Discussion
HPLC and HR-LC/MS analysis confirmed the presence
of Exo-MS with some impurities. NMR technique not
being sensitive, low concentrations of Exo-MS could not
allow a clear correlation in TOCSY, though threonine,
β-alanine and γ1β-ornithine could be deciphered.
Fig. 4 HPLC of ferrioxamine B. Ferrioxamine B at 1.0 μg/mL concentration was analysed by injecting 10 μL in Waters Xterra MS MS HPLC system.
The column used was C18, 5 µm, 4.6 x 100 mm, at a flow-rate of 1.5 mL per min. Solvent system was 0.1% trifluoroacetic acid (TFA) in water (v/v)
for first 10 min, followed by equal volumes of 0.1% aqueous TFA and acetonitrile (1:1 v/v) for the next 30 min. And then 0.1% TFA in water (v/v)
for the next 10 min, peaks monitored at 420nm. The chromatogram showed a single peak between 15-20 min
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HPLC analysis of ferri-MBS indicated about 98% pur-
ity. When the siderophore is complexed with iron, the
red colored complex shows maximum absorbance at
450 nm, whereas the peptide bonds of MBS have an ab-
sorbance maximum at 220 nm. The peaks seen at
A220nm corresponded with the peaks observed at A450 nm
indicating pure MBS preparation. These were similar to
the peaks obtained for MBS by Ratledge and Ewing [13].
Only one peak was obtained in the HPLC analysis of
ferrioxamine-B indicating it was pure.
To be used for iron-depletion from microbial environ-
ments, siderophores need to be in a desferri form and
not saturated with iron. Therefore, desferri form of side-
rophores were obtained using the isolation protocols for
Exo-MS and MBS, but without the addition of iron dur-
ing the entire isolation process. Iron was added to small
aliquots only for determining purity and concentration
of the siderophores.
Effect of Exo-MS, MBS, and DFO-B on mammalian cell
lines
Non-malignant cells and malignant cells lines were
used to study the effect of the iron-chelators on
mammalian cells. The exposure with the siderophores
was done for 18–24 h because the average time of
division for the mammalian cells in vitro is 18–28 h.
Besides, siderophores are not respiratory inhibitors, and
are expected to affect proliferation of cells. When some
pathogenic bacteria were treated with these siderophores
for 18–24 h, they were inhibited (manuscript under
preparation). This was also taken into consideration
whilst subjecting mammalian cells to siderophores for
18–24 h.
The experiments with mammalian cells showed that
concentrations of Exo-MS and DFO-B that significantly
inhibited the murine cancer cell line RAW 264.7 were
not inhibitory to the normal cell line NIH/3 T3. It
should be noted that both Exo-MS and DFO-B had no
significant effect on the non-malignant human cell line
HEK 293 up to 0.5 mg/mL and 1 mg/mL, respectively.
DFO-B also inhibited the proliferation of human
breast cancer (MCF-7) and human leukemia (K 562) cell
lines. However, it had no effect on human liver cancer
cell line (HEPG2) even at 10 mg/mL. Exo-MS did not
inhibit any of the human cancer cell lines tested. DFO-B
has already been shown to have anti-proliferative effect
on cancer cells [14], and hence was used here as a
control.
Fig. 5 Effect of Exo-MS on murine cell lines RAW 264.7 and NIH/3 T3. The results of MTT assay were plotted using statistical analytical software - GraphPad
Prism 7.01 and SigmaStat 4.0. The readings of control wells containing untreated cells were considered as 100% survival. a A statistically significant decrease
in the percent survival of macrophage cancer cell line RAW 264.7 was seen at Exo-MS concentrations at 0.2 mg/mL (P <0.001). b No statistically significant
reduction in the percent survival of normal mouse fibroblast cell line, NIH/3 T3 was seen at Exo-MS concentrations up to 0.5 mg/mL. c IC50 of Exo-MS =
0.128 mg/mL for RAW 264.7
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Fig. 6 Effect of DFO-B on murine cell lines RAW 264.7 and NIH/3 T3. The results of MTT assay were plotted using statistical analytical software - GraphPad
Prism 7.01 and SigmaStat 4.0. The readings of control wells containing untreated cells were considered as 100% survival. a A statistically significant decrease
in the percent survival of macrophage cancer cell line RAW 264.7 was seen at DFO-B concentrations up to 1.0 mg/mL (P <0.001). b No statistically
significant decrease in the percent survival of normal mouse fibroblast cell line, NIH/3 T3 was seen at DFO-B concentrations up to 1.0 mg/mL. c IC50 of
DFO-B for RAW 264.7 was = 0.366 mg/mL
Fig. 7 Effect of Exo-MS on human cell lines K 562, MCF-7 and HEK 293. The results of MTT assay were plotted using statistical analytical software -
GraphPad Prism 7.01 and SigmaStat 4.0. The readings of control wells containing untreated cells were considered as 100% survival. No statistically
significant decrease in the percent survival was observed for (a) human leukemia cell K 562 at Exo-MS concentrations up to 0.5 mg/mL (b) breast
cancer cell line MCF-7 at Exo-MS concentrations up to 1.0 mg/mL and (c) normal embryonic kidney cell line HEK 293 at Exo-MS concentrations
up to 0.5 mg/mL
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When ferri-siderophores were evaluated for activity
using the same MTT assay, no inhibitory effect on the
cell proliferation was observed (data not shown). In this
form, the siderophores were already saturated with iron,
and therefore, could not deprive the cells of iron.
Earlier, some investigators have reported that a lipid-
soluble siderophore from Mycobacterium tuberculosis
(Mtb), mislabelled by the authors as (desferri-)exochelin
772SM, induces death by apoptosis in human breast
cancer cells without harming normal breast epithelial
cells [15]. However, the correct term for the siderophore
referred to by the authors should have been ‘Carboxymy-
cobactin’, since water-soluble exochelin is not produced
by Mtb.
Hoke et al. reported that DFO-B could be used as an
adjunct to chemotherapy along with doxorubicin drug to
inhibit breast tumor growth without any cardiotoxicity
[16]. DFO-B was also found to be cytotoxic to malignant
cells of neural origin [17, 18]. When DFO-B was given
during the initial stages of tumor formation, it resulted
in either regression or slower tumor growth due to de-
crease in intracellular Fe3+ concentration [19]. DFO-B
was found to be inhibitory to leukemia cells in vivo as
evident from the reduction in the cell numbers [20].
Since the water-soluble siderophores Exo-MS and
DFO-B had no effect on HEPG2 even at high concentra-
tions, effect of the lipid-soluble siderophore MBS was
evaluated on HEPG2. MBS significantly decreased the
Fig. 9 Effect of MBS, Exo-MS, and DFO-B on human liver cancer cell line HEPG2. The results of MTT assay were plotted using statistical analytical
software - GraphPad Prism 7.01 and SigmaStat 4.0. The readings of control wells containing untreated cells were considered as 100% survival. a A
statistically significant decrease in viability of the cells at MBS concentrations from 10 μg/mL onwards was observed (P <0.001). b and c No
statistically significant difference was observed in percent survival of HEPG2 at the Exo-MS and DFO-B concentrations up to 0.5 mg/mL and
10 mg/mL, respectively
Fig. 8 Effect of DFO-B on human cell lines K 562, MCF-7 and HEK 293. The results of MTT assay were plotted using statistical analytical software -
GraphPad Prism 7.01 and SigmaStat 4.0. The readings of control wells containing untreated cells were considered as 100% survival. a For human
leukemia cell K 562, a statistically significant reduction in cell survival at DFO-B concentration of 0.5 mg/mL. b A statistically significant decrease in
cell survival was seen with breast cancer cell line MCF-7 at DFO-B concentration of 1.0 mg/mL was observed (P <0.01). c No statistically significant
decrease in the percent survival of normal embryonic kidney cell line HEK 293 was observed at DFO-B concentration upto 1.0 mg/mL
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percent survival of HEPG2 cells at very low concentra-
tions (10–20 μg/mL). This concentration is almost 50–
1000 times lower than Exo-MS and DFO-B concentra-
tions that inhibited RAW 264.7 cell line. Due to its lipo-
philic nature, MBS may traverse eukaryotic cell
membrane. This lipid-soluble characteristic makes MBS
much more efficient at lower concentrations in trapping
intracellular iron than the hydrophilic siderophores.
Since very low concentrations of MBS showed anti-
proliferative activity in vitro, it would be interesting to
investigate its effects in vivo.
In the light of our results with the lipid-soluble MBS,
conjugating water-soluble siderophores with lipid mole-
cules may make them more effective against tumor cells.
These siderophore conjugates could be evaluated as anti-
cancer agents by themselves, or along with other therapies.
Conclusions
These investigations provide a “proof of concept” that
iron chelation therapy may be useful against malignant
cells without any significant cytotoxicity on non-
malignant cells. The anti-proliferative effect of sidero-
phores on malignant cells needs further experimental
and clinical studies to determine their role and utility in
cancer treatment. The in-vivo toxicity of water-soluble
siderophores may not be of concern, since DFO-B has
already been approved by US-FDA for treating second-
ary iron-overload in patients suffering from thalassemia.
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